在结直肠癌进展中的lysyl氧化酶抑制剂
Muxian Liu1, Jie Wang1, Meihong Liu1
1Department of Gastroenterology, Dongguan Tungwah Hospital, Dongguan City 523000, Guangdong, China.
Translational oncology
|December 15, 2024
概括
氨酸氧化酶 (LOX) 酶在结直肠癌 (CRC) 的进展中至关重要. 用抑制剂向这些酶显示出作为补充CRC治疗策略的希望.
科学领域:
- 生物化学和分子生物学
- 在瘤学瘤学.
- 细胞外矩阵生物学 细胞外矩阵生物学
背景情况:
- lysine oxidase (LOX) 酶家族,包括LOX和LOX-like (LOXL) 成员,对于细胞外基质 (ECM) 中的原和弹性素的交叉连接至关重要.
- 在各种癌症中观察到LOX家族成员的失调,特别是结肠直肠癌 (CRC),它们影响细胞迁移,增殖,入侵和转移.
- 向LOX家族蛋白质已经成为癌症治疗的有前途的治疗策略.
研究的目的:
- 审查LOX酶在结直肠癌的发展和进展中的作用.
- 讨论最近在LOX/LOXL抑制剂开发方面的进展.
- 突出LOX/LOXL抑制剂作为CRC的有效和补充治疗的潜力.
主要方法:
- 关于LOX酶在癌症中的功能研究的文献综述.
- 对结直肠癌中LOX家族成员失调的研究分析.
- 检查LOX/LOXL抑制剂的设计和应用方面的最新进展.
主要成果:
- 洛克斯酶在结直肠癌的发病过程中起着重要作用,影响癌症的关键特征.
- 已经开发了几种向LOX/LOXL酶的特定抑制剂,在临床前研究中显示出潜力.
- 抑制LOX酶可以阻碍癌细胞的迁移,增殖和入侵.
结论:
- 洛克斯酶是结直肠癌进展中的关键调节剂.
- LOX/LOXL抑制剂代表着结直肠癌的潜在治疗途径.
- 对LOX/LOXL抑制剂的进一步研究可能会导致CRC的新型补充治疗策略.
更多相关视频
12:37Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
Published on: September 11, 2012
46.8K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
